Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 126 Published: June 30, 2022 Report Code: GDGMDHC22204IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome – Drugs In Development, 2022, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 6, 1, 27 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).

– The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Actinogen Medical Ltd

    Allos Pharma Inc

    Anavex Life Sciences Corp

    Anima Biotech Inc

    Astellas Pharma Inc

    Autifony Therapeutics Ltd

    Avekshan LLC

    Cognosetta Inc

    Confluence Pharmaceuticals LLC

    Connecta Therapeutics SL

    DRI Biosciences Corp

    Epigen Biosciences Inc

    GEXVal Inc

    GSK plc

    Healx Ltd

    Hua Medicine Shanghai Ltd

    Jazz Pharmaceuticals Plc

    Lysogene SAS

    Neuren Pharmaceuticals Ltd

    Neurochlore

    NeuroNascent Inc

    Novartis AG

    Paxmedica Inc

    Pilz Bioscience Corp

    Prilenia Therapeutics Development Ltd

    Prous Institute for Biomedical Research SA

    Puretech Health Plc

    Quris Technologies Ltd

    Recursion Pharmaceuticals Inc

    RespireRx Pharmaceuticals Inc

    Sentinel Oncology Ltd

    Synaptogenix Inc

    Takeda Pharmaceutical Co Ltd

    Taysha Gene Therapies Inc

    Tetra Therapeutics

    Triplet Therapeutics Inc

    Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fragile X Syndrome – Overview

Fragile X Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fragile X Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fragile X Syndrome – Companies Involved in Therapeutics Development

Fragile X Syndrome – Drug Profiles

Fragile X Syndrome – Dormant Projects

Fragile X Syndrome – Discontinued Products

Fragile X Syndrome – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fragile X Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Fragile X Syndrome – Pipeline by Actinogen Medical Ltd, 2022

Fragile X Syndrome – Pipeline by Allos Pharma Inc, 2022

Fragile X Syndrome – Pipeline by Anavex Life Sciences Corp, 2022

Fragile X Syndrome – Pipeline by Anima Biotech Inc, 2022

Fragile X Syndrome – Pipeline by Astellas Pharma Inc, 2022

Fragile X Syndrome – Pipeline by Autifony Therapeutics Ltd, 2022

Fragile X Syndrome – Pipeline by Avekshan LLC, 2022

Fragile X Syndrome – Pipeline by Cognosetta Inc, 2022

Fragile X Syndrome – Pipeline by Confluence Pharmaceuticals LLC, 2022

Fragile X Syndrome – Pipeline by Connecta Therapeutics SL, 2022

Fragile X Syndrome – Pipeline by DRI Biosciences Corp, 2022

Fragile X Syndrome – Pipeline by Epigen Biosciences Inc, 2022

Fragile X Syndrome – Pipeline by GEXVal Inc, 2022

Fragile X Syndrome – Pipeline by GSK plc, 2022

Fragile X Syndrome – Pipeline by Healx Ltd, 2022

Fragile X Syndrome – Pipeline by Hua Medicine Shanghai Ltd, 2022

Fragile X Syndrome – Pipeline by Jazz Pharmaceuticals Plc, 2022

Fragile X Syndrome – Pipeline by Lysogene SAS, 2022

Fragile X Syndrome – Pipeline by Neuren Pharmaceuticals Ltd, 2022

Fragile X Syndrome – Pipeline by Neurochlore, 2022

Fragile X Syndrome – Pipeline by NeuroNascent Inc, 2022

Fragile X Syndrome – Pipeline by Novartis AG, 2022

Fragile X Syndrome – Pipeline by Paxmedica Inc, 2022

Fragile X Syndrome – Pipeline by Pilz Bioscience Corp, 2022

Fragile X Syndrome – Pipeline by Prilenia Therapeutics Development Ltd, 2022

Fragile X Syndrome – Pipeline by Prous Institute for Biomedical Research SA, 2022

Fragile X Syndrome – Pipeline by Puretech Health Plc, 2022

Fragile X Syndrome – Pipeline by Quris Technologies Ltd, 2022

Fragile X Syndrome – Pipeline by Recursion Pharmaceuticals Inc, 2022

Fragile X Syndrome – Pipeline by RespireRx Pharmaceuticals Inc, 2022

Fragile X Syndrome – Pipeline by Sentinel Oncology Ltd, 2022

Fragile X Syndrome – Pipeline by Synaptogenix Inc, 2022

Fragile X Syndrome – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Fragile X Syndrome – Pipeline by Taysha Gene Therapies Inc, 2022

Fragile X Syndrome – Pipeline by Tetra Therapeutics, 2022

Fragile X Syndrome – Pipeline by Triplet Therapeutics Inc, 2022

Fragile X Syndrome – Pipeline by Zynerba Pharmaceuticals Inc, 2022

Fragile X Syndrome – Dormant Projects, 2022

Fragile X Syndrome – Dormant Projects, 2022 (Contd..1)

Fragile X Syndrome – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Fragile X Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.